Retatrutide (LY3437943) — Triple Incretin Receptor Agonist Research Peptide | Klene Peptides
For Research Use Only | Not for Human or Veterinary Administration
Retatrutide is rapidly becoming one of the most closely watched molecules in metabolic and cardiometabolic research. As a first-in-class triple incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, it has demonstrated dose-dependent weight reduction and glycemic improvements in Phase II clinical trials that significantly exceed those observed with dual agonists. Klene Peptides supplies USA research laboratories with retatrutide of verified analytical integrity — shipped same day.
Every vial from Klene Peptides includes:
- ≥99.3% purity — verified by HPLC (High-Performance Liquid Chromatography)
- Molecular identification via HPLC-MS (High-Performance Liquid Chromatography - Mass Spectrometry)
- Same-day shipping for all USA orders
Why Labs Choose Retatrutide: Comparative Efficacy in Context
The metabolic research landscape has evolved rapidly from GLP-1 monotherapy to dual GIP/GLP-1 agonism (tirzepatide) and now to triple receptor engagement. Retatrutide’s differentiation lies in the additive contribution of glucagon receptor agonism, which drives hepatic fat mobilization and energy expenditure through mechanisms not accessible to GLP-1 or GIP pathways alone.
Receptor Agonism Comparison Across Incretin Research Peptides
| Compound | GLP-1R | GIPR | GCGR | Peak Clinical Weight Reduction |
|---|---|---|---|---|
| Semaglutide | ✔ High | — | — | ~17% (STEP 1) |
| Tirzepatide | ✔ High | ✔ High | — | ~22.5% (SURMOUNT-1) |
| Retatrutide | ✔ High | ✔ High | ✔ Moderate | ~24.2% (Phase II, 48 wk) |
Source: Jastreboff et al., NEJM 2023; Eli Lilly Phase II trial NCT04881760
Why Glucagon Receptor Activation Matters
Glucagon receptor agonism within a balanced triple-agonist framework offers mechanistic advantages distinct from isolated GLP-1 activity:
| Mechanism | Research Implication |
|---|---|
| Hepatic glycogenolysis upregulation | Fasting glucose modeling in NAFLD/NASH contexts |
| Brown adipose thermogenesis activation | Energy expenditure quantification independent of caloric restriction |
| Lipolysis acceleration (adipocyte level) | Lipid flux studies in dyslipidemia models |
| Appetite suppression (complementary to GLP-1) | Additive satiety signaling investigation |
The co-agonist design prevents the hyperglycemia typically associated with isolated glucagon receptor stimulation by pairing it with GLP-1R and GIPR mediated insulin sensitization — a pharmacological balance that researchers are actively characterizing.
What Labs Are Investigating: Current Research Applications
Obesity & Metabolic Weight Reduction
The pivotal Phase II trial (NEJM, 2023) enrolled 338 adults with obesity (BMI ≥27) without diabetes. At 48 weeks, participants receiving the highest dose (12 mg) achieved a mean weight reduction of 24.2% — a result that surpassed tirzepatide’s published SURMOUNT-1 data and is driving substantial follow-on investigation.
Active research questions include:
- Does glucagon receptor-driven thermogenesis account for the additional ~2% weight reduction beyond dual agonism?
- What are the lean mass preservation profiles at maximum dosing?
- How does retatrutide interact with gut microbiome composition over 12–24 months?
Type 2 Diabetes & Glycemic Control
In a parallel cohort of 281 participants with T2DM, retatrutide produced statistically significant HbA1c reductions across all dose groups:
| Dose Group | HbA1c Reduction (%) | Fasting Glucose Reduction (mg/dL) |
|---|---|---|
| 0.5 mg | −1.3% | −24 |
| 4 mg | −1.9% | −38 |
| 8 mg | −2.2% | −46 |
| 12 mg | −2.6% | −58 |
Eli Lilly Phase II (T2DM arm), NCT04881760
NAFLD / NASH and Hepatic Fat Research
The glucagon receptor component of retatrutide’s activity is particularly relevant in liver fat research. GCGR stimulation increases hepatic fatty acid oxidation and reduces de novo lipogenesis through downstream modulation of PPAR-α and FGF21. Preclinical and early clinical data suggest hepatic fat reduction of 60–80% in treated subjects — a parameter under active investigation in the NASH research space.
Cardiovascular & Cardiometabolic Research
| Parameter | Observed Direction | Mechanism Under Investigation |
|---|---|---|
| LDL-C | Reduction | Hepatic lipid clearance via GCGR/GIPR |
| Triglycerides | Significant reduction | Lipolytic and lipogenic pathway modulation |
| Systolic BP | Modest reduction | GLP-1R-mediated vasodilation |
| Cardiac output | Neutral to improved | GLP-1R cardioprotective signaling |
Parameter
- LDL-C
- Triglycerides
- Systolic BP
- Cardiac output
Observed Direction
- Reduction
- Significant reduction
- Modest reduction
- Neutral to improved
Mechanism Under Investigation
- Hepatic lipid clearance via GCGR/GIPR
- Lipolytic and lipogenic pathway modulation
- GLP-1R-mediated vasodilation
- GLP-1R cardioprotective signaling
Phase III CVOT (cardiovascular outcomes trial) data is anticipated, and research groups are pre-positioning mechanistic studies.
Molecular Science: Structure, Binding Kinetics & Pharmacokinetics
Chemical Identity
| Parameter | Value |
|---|---|
| IUPAC Name | Long-chain fatty acid–modified 39-residue glucagon analog |
| Molecular Weight | ~4,862 Da (free base) |
| Sequence Basis | Glucagon scaffold with selective GIP and GLP-1 receptor pharmacophore insertions |
| Lipid Modification | C18 fatty diacid via gamma-glutamic acid/mini-PEG linker |
| CAS (research) | 2381016-73-3 |
| Storage | Lyophilized: −20°C; Reconstituted: 2–8°C, use within 28 days |
Receptor Binding Kinetics
| Receptor | Affinity (EC₅₀) | Relative Potency vs. Native Ligand |
|---|---|---|
| GLP-1R | ~0.07 nM | Equivalent to semaglutide-class |
| GIPR | ~0.4 nM | High (near-equivalent to tirzepatide) |
| GCGR | ~1.2 nM | Moderate (intentionally attenuated to prevent hyperglycemia) |
Ki values from Eli Lilly preclinical pharmacology disclosure, 2022
Pharmacokinetic Profile
| Parameter | Value | Notes |
|---|---|---|
| Bioavailability (SC) | ~85–90% | Estimated from Phase I modeling |
| Tmax | ~48–72 hours | Albumin-binding extends absorption |
| Half-life (t½) | ~6 days | Supports once-weekly dosing |
| Volume of Distribution | ~12–15 L | Primarily extravascular |
| Clearance | Renal + proteolytic | No CYP450 hepatic metabolism |
| Protein Binding | >97% (albumin) | Fatty acid chain-mediated |
Laboratory Use Protocols
Reconstitution Reference
| Lyophilized Amount | Bacteriostatic Water | Resulting Concentration |
|---|---|---|
| 2 mg | 1.0 mL | 2.0 mg/mL (2000 mcg/mL) |
| 5 mg | 2.5 mL | 2.0 mg/mL |
| 10 mg | 5.0 mL | 2.0 mg/mL |
Reconstitution Protocol:
- Allow vial to equilibrate to room temperature (~15 minutes)
- Inject bacteriostatic water along the vial wall — do not inject directly onto lyophilized cake
- Gently swirl until fully dissolved — do not vortex
- Inspect for clarity; discard if particulate matter is present
- Store reconstituted solution at 2–8°C; use within 28 days
Research Dosing Reference (Published Clinical Data Context)
| Phase II Dose Group | Weekly Equivalent | Cumulative Duration | Observed Weight Loss |
|---|---|---|---|
| Low (0.5 mg) | 0.5 mg SC | 48 weeks | ~8.7% |
| Mid-low (2 mg) | 2 mg SC | 48 weeks | ~17.3% |
| Mid-high (8 mg) | 8 mg SC | 48 weeks | ~22.8% |
| High (12 mg) | 12 mg SC | 48 weeks | ~24.2% |
For research reference only — not dosing recommendations. Source: Jastreboff et al., NEJM 2023
Stability & Handling Summary
| Condition | Duration | Notes |
|---|---|---|
| Lyophilized / −20°C | 24+ months | Protect from light and humidity |
| Lyophilized / +4°C | 3 months | Short-term lab storage acceptable |
| Reconstituted / +4°C | 28 days | Avoid freeze-thaw cycling |
| Reconstituted / room temp | 24 hours | Use promptly after preparation |
Klene Peptides Quality Standards
Every batch supplied by Klene Peptides is verified against the following analytical benchmarks:
Certificate of Analysis — Standard Parameters
Every retatrutide batch supplied by Klene Peptides undergoes rigorous analytical verification before release. Our commitment to research-grade integrity means your assay data reflects the peptide — not contamination, degradation, or mislabeling.
| Test | Specification | Method |
|---|---|---|
| Purity | ≥99.3% | HPLC (High-Performance Liquid Chromatography) |
| Molecular Identification | Confirmed | HPLC-MS (High-Performance Liquid Chromatography – Mass Spectrometry) |
| Water Content | <1.5% | — |
What Every Klene Peptides Order Includes
- Lot-specific Certificate of Analysis traceable to synthesis batch
- Verified cold-chain shipping — all orders dispatched with appropriate cold-pack packaging for peptide integrity in transit
- Same-day fulfillment — orders placed before cutoff ship the same business day
Ordering Retatrutide for Your Research Program
Important Research Compliance Notice
Scientific References
- Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972
- Urva S, et al. "Pharmacokinetics and Pharmacodynamics of LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in Patients with Type 2 Diabetes." Diabetes, Obesity and Metabolism. 2022. DOI: 10.1111/dom.14932
- Coskun T, et al. "LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept." Molecular Metabolism. 2018;18:3-14.
- Finan B, et al. "Glucagon Receptor Signaling and Glucagon Resistance." International Journal of Molecular Sciences. 2016;17(10):1726.
- Nauck MA, Meier JJ. "The Incretin Effect in Healthy Individuals and Those with Type 2 Diabetes." The Lancet Diabetes & Endocrinology. 2016;4(6):525-536.
- PubChem. Retatrutide. CID: 2517618. https://pubchem.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT04881760. U.S. National Library of Medicine.